Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 5/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 5/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 4/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 4/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952308 | 1.00 | ERN1 (0.35) | ERN1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL412602 | 0.83 | ERN1 (0.35) | ERN1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL29954903 | 0.83 | ERN1 (0.35) | ERN1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL29411195 | 0.78 | TDP1 (0.45) | ERN1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL899188 | 0.78 | TDP1 (0.45) | ERN1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL15332623 | 0.75 | ERN1 (0.41) | ERN1TDP1 | |
| SCHEMBL29954366 | 0.75 | TDP1 (0.35) | ERN1TDP1 | |
| SCHEMBL10322950 | 0.75 | TDP1 (0.35) | ERN1TDP1 | |
| SCHEMBL29958162 | 0.75 | ERN1 (0.44) | ERN1 | |
| SCHEMBL20330598 | 0.75 | ERN1 (0.44) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| WO-2024160276-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| WO-2012096813-A1 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012044567-A2 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | ERN1 630/4885KCNQ3 3598/4885KCNQ2 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.